Integer Holdings Co. (NYSE:ITGR) Receives $120.50 Average PT from Analysts

Shares of Integer Holdings Co. (NYSE:ITGR) have been given a consensus recommendation of “Moderate Buy” by the six analysts that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $120.50.

Several research analysts recently issued reports on ITGR shares. Benchmark raised their target price on Integer from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Thursday, March 28th. CL King started coverage on Integer in a research note on Thursday, March 14th. They issued a “buy” rating and a $137.00 price target for the company. Bank of America raised Integer from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $105.00 to $135.00 in a research note on Monday, April 15th. Finally, KeyCorp increased their target price on shares of Integer from $123.00 to $139.00 and gave the company an “overweight” rating in a research report on Tuesday, April 9th.

Institutional Investors Weigh In On Integer

Several large investors have recently added to or reduced their stakes in ITGR. Vanguard Group Inc. boosted its holdings in shares of Integer by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 3,843,992 shares of the medical equipment provider’s stock worth $301,484,000 after buying an additional 15,300 shares in the last quarter. Victory Capital Management Inc. boosted its stake in Integer by 8.9% during the third quarter. Victory Capital Management Inc. now owns 1,632,549 shares of the medical equipment provider’s stock worth $128,041,000 after acquiring an additional 133,898 shares in the last quarter. FMR LLC boosted its stake in Integer by 12.8% during the third quarter. FMR LLC now owns 863,938 shares of the medical equipment provider’s stock worth $67,759,000 after acquiring an additional 97,851 shares in the last quarter. Fuller & Thaler Asset Management Inc. grew its holdings in Integer by 497.0% in the third quarter. Fuller & Thaler Asset Management Inc. now owns 536,343 shares of the medical equipment provider’s stock worth $42,065,000 after purchasing an additional 446,508 shares during the period. Finally, abrdn plc increased its stake in Integer by 0.6% in the fourth quarter. abrdn plc now owns 520,646 shares of the medical equipment provider’s stock valued at $51,586,000 after purchasing an additional 3,013 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Stock Performance

Integer stock opened at $117.92 on Friday. The business has a 50 day moving average of $112.31 and a 200-day moving average of $99.32. The company has a market capitalization of $3.95 billion, a P/E ratio of 43.84, a P/E/G ratio of 1.61 and a beta of 1.10. Integer has a 1 year low of $69.40 and a 1 year high of $121.53. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71.

Integer (NYSE:ITGR) last posted its earnings results on Thursday, February 15th. The medical equipment provider reported $1.39 earnings per share for the quarter, topping analysts’ consensus estimates of $1.34 by $0.05. The firm had revenue of $413.15 million for the quarter, compared to analyst estimates of $409.04 million. Integer had a net margin of 5.68% and a return on equity of 10.80%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.11 EPS. On average, equities research analysts predict that Integer will post 5.31 earnings per share for the current year.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.